Lilly neuroscience president says the company is interested in studying and improving ibogaine through research and development

Eli Lilly is interested in research and development aimed at improving ibogaine's profile, according to neuroscience president Carole Ho. She made the comments at the Psychedelic Healthcare Forum in New York City, indicating that the pharmaceutical company is considering ibogaine as a potential area for scientific and commercial investment. The discussion follows Lilly's reported $2.8 billion acquisition of AtaiBeckley, providing corporate context for its growing engagement with psychedelic medicine. The supplied material does not specify which aspects of ibogaine Lilly wants to improve, what studies may be planned, or whether any investment has been finalized. It therefore supports a report of stated interest rather than evidence of a launched program or clinical development strategy.